A | TRAIL | Â | |||
Untreated | 50Â ng/mL | 100Â ng/mL | ANOVA | ||
FCCP (μM) | Vehicle | 1.00 ± 0.02a | 0.90 ± 0.06a | 0.93 ± 0.02a | 0.1901 |
1.0 | 0.98 ± 0.04a | 0.85 ± 0.04a* | 0.90 ± 0.02a | 0.0448 | |
2.5 | 0.94 ± 0.03a | 0.75 ± 0.04a** | 0.79 ± 0.01b** | 0.0011 | |
5.0 | 0.91 ± 0.02a | 0.69 ± 0.03b** | 0.72 ± 0.02b** | 7.16E-05 | |
ANOVA | Â | 0.1335 | 0.0143 | 1.28E-06 | Â |
B | Cisplatin | Â | |||
Untreated | 1 μM | 10 μM | ANOVA | ||
FCCP (μM) | Vehicle | 1.00 ± 0.01a | 0.95 ± 0.07a | 1.07 ± 0.04a | 0.2609 |
1.0 | 0.96 ± 0.04a,b | 0.85 ± 0.03a | 0.99 ± 0.04a | 0.1036 | |
2.5 | 0.85 ± 0.00b,c | 0.91 ± 0.05a | 0.95 ± 0.04a | 0.2008 | |
5.0 | 0.80 ± 0.02c | 0.78 ± 0.04a | 0.88 ± 0.02b | 0.1185 | |
ANOVA | Â | 0.0012 | 0.1549 | 0.0384 | Â |
C | TRAIL | Â | |||
Untreated | 50Â ng/mL | 100Â ng/mL | ANOVA | ||
Oligomycin (μM) | Vehicle | 1.0 ± 0.04a | 0.97 ± 0.04a | 0.95 ± 0.02a | 0.5931 |
1.0 | 0.90 ± 0.01a | 0.85 ± 0.01a | 0.80 ± 0.01b** | 0.006 | |
2.5 | 0.96 ± 0.04a | 0.82 ± 0.05a | 0.81 ± 0.00b | 0.0483 | |
5.0 | 0.86 ± 0.03a | 0.82 ± 0.08a | 0.84 ± 0.04b | 0.9093 | |
ANOVA | Â | 0.0507 | 0.2121 | 0.0062 | Â |
Cisplatin | Â | ||||
 |  | Untreated | 1 μM | 10 μM | ANOVA |
Oligomycin (μM) | Vehicle | 1.00 ± 0.03a | 0.88 ± 0.09a | 0.94 ± 0.02a | 0.3459 |
1.0 | 0.92 ± 0.02a | 0.85 ± 0.01a* | 0.84 ± 0.01b* | 0.0129 | |
2.5 | 0.91 ± 0.02b | 0.84 ± 0.03a | 0.89 ± 0.01a | 0.1578 | |
5.0 | 0.91 ± 0.00b | 0.88 ± 0.03a | 0.84 ± 0.03b | 0.2232 | |
ANOVA | Â | 0.0279 | 0.9114 | 0.0135 | Â |